MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Pressure Sensor Insole Gait Assessment for Parkinson’s Disease patients: A pilot study

Z. Kefalopoulou, C. Chatzaki, V. Skaramagkas, E. Chroni, N. Tachos, DI. Fotiadis, M. Tsiknakis (Patras, Greece)

Meeting: 2022 International Congress

Abstract Number: 369

Keywords: Gait disorders: Clinical features, Parkinson’s

Category: Technology

Objective: To assess the correlations between gait characteristics obtained from pressure sensor insoles, and clinical assessments of motor features in Parkinson’s Disease (PD) patients.

Background: Gait analysis is of high importance for the management of PD. Latest advances include the use of wearable sensing systems to support the precise and objective assessment of gait.

Method: PD patients (Hoehn & Yahr stages 1-4) were recruited from the Movement Disorders Clinic, Patras University Hospital, Greece. All participants were assessed during the OFF and ON medication conditions. A ten-meter route at a normal pace of walking was performed by all participants, and for 4 repetitions in each state, while wearing a validated sensor insole system (incorporating 16 pressure sensors). Sixteen gait temporal and spatial characteristics (step number, right & left step duration, stride duration, stance time, swing time, single & double support time, step length, stride length, gait cycle, step velocity, gait velocity, step cadence, walk ratio) were calculated. These were correlated with Part III MDS-Unified Parkinson´s Disease Rating Scale (MDS-UPDRS) total scores and sub-scores of interests (Axial and Bradykinesia), as well as medication state. A mixed linear model with Least Significant Difference adjustment was employed. Level of statistical significance was set at p<0.05. Safety and wearability of the device were also measured.

Results: Nineteen PD patients (14 males) with mean age 63±11.5 years, disease duration 11.0±10 years and levodopa equivalent dose 638±289.8 were included. Total UPDRS-III score was 41.7±20 and 30.3±20.3 during OFF and ON conditions. Mixed linear model analysis revealed a significant correlation between medication state and 6, between axial score and 12, between bradykinesia score and 13, and between UPDRS-III total score and 10 out of the 16 features. Further within the two medication states analysis showed significant interactions between axial, bradykinesia and UPDRS-III total score and 2, 14 and 8 features, respectively. There were no issues regarding the wearability of the device and no adverse events occurred.

Conclusion: The experimental results show correlations between the different MDS-UPDRS subsets and the gait temporal and spatial characteristics. Therefore, it is positively evidenced that wearable sensing systems could support the clinical gait assessment and that further research is needed.

To cite this abstract in AMA style:

Z. Kefalopoulou, C. Chatzaki, V. Skaramagkas, E. Chroni, N. Tachos, DI. Fotiadis, M. Tsiknakis. Pressure Sensor Insole Gait Assessment for Parkinson’s Disease patients: A pilot study [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/pressure-sensor-insole-gait-assessment-for-parkinsons-disease-patients-a-pilot-study/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/pressure-sensor-insole-gait-assessment-for-parkinsons-disease-patients-a-pilot-study/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley